- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05889741
Combinando bloqueio do gânglio estrelado com exposição prolongada para PTSD
Combinando bloqueio do gânglio estrelado com exposição prolongada para TEPT: um ensaio clínico randomizado
The goal of this clinical trial is to compare the combination of Massed Prolonged Exposure (PE); a behavioral therapy for PTSD) and a stellate ganglion block (SGB; an injection of a local anesthetic into the front of the neck) with Massed Prolonged Exposure and a sham injection in a sample of military service members or retirees with PTSD. The main questions it aims to answer are: (1) Does the addition of an SGB improve treatment outcomes associated with Massed PE and (2) Do differences in psychophysiological arousal during the exposure portion of treatment help explain treatment outcomes for PTSD. Participants will receive ten 90-minute session of Massed PE. Between the first and second Massed PE sessions, half of the participants will receive a SGB, and half will receive a sham SGB.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Massed PE will be conducted by master-level or doctoral-level therapists. Participants will meet with their providers for individual, 90-minute sessions. They will then be asked to complete out-of-session treatment assignments throughout the rest of the day. Between the individual therapy session and out-of-session treatment assignments, participants will engage in approximately four to six hours of treatment per day, Monday through Friday, for two weeks. Each participant will also be offered three booster sessions at 1-, 3-, and 7-weeks posttreatment.
The stellate ganglion block injection or the sham SGB will be administered between the first and second massed PE session by qualified medical personnel as per standard operating procedure for the placement of a stellate ganglion block. A research nurse will be in attendance during the procedure and for an hour recovery period following the block administration.
Assessments will be administered at pretreatment, during treatment, at posttreatment, and at 1-, 3-, and 6-months following the completion of PE. The primary outcome assessment will be 1-month following the completion of PE. Following this assessment, participants randomized to the sham SGB arm of the study will be offered an SGB with ropivacaine.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
- Nome: Amanda Flores
- Número de telefone: 210-562-6726
- E-mail: floresa13@uthscsa.edu
Locais de estudo
-
-
Texas
-
Fort Hood, Texas, Estados Unidos, 76544
- Recrutamento
- Carl R. Darnall Army Medical Center
-
Contato:
- Paul Fowler
- Número de telefone: 726-225-5520
- E-mail: fowlerp@uthscsa.edu
-
Investigador principal:
- Caleb Dickinson, DO
-
Fort Sam Houston, Texas, Estados Unidos, 78234
- Recrutamento
- Brook Army Medical Center (BAMC)
-
Contato:
- Wilson B Pfeiffer, DO
- Número de telefone: 210-916-8256
- E-mail: wilson.b.pfeiffer.mil@health.mil
-
Investigador principal:
- Wilson B Pfeiffer, Do
-
San Antonio, Texas, Estados Unidos, 78229
- Recrutamento
- University of Texas Health Science Center at San Antonio
-
Contato:
- Amanda Flores
- Número de telefone: 210-562-6726
- E-mail: floresa13@uthscsa.edu
-
Investigador principal:
- Alan Peterson, PhD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Active duty and retired military service members ages 18-65 years
- PTSD diagnosis as assessed by Clinician-Administered Posttraumatic Stress Scale
- Able to speak and read English (due to standardization of outcome measures)
- Defense Enrollment Eligibility Reporting System (DEERS)-eligible to receive care at a military treatment facility (MTF) where the stellate ganglion block will be placed.
Exclusion Criteria:
- Current suicidal ideation severe enough to warrant immediate attention (as determined by the Depressive Symptoms Index - Suicidality Subscale and the Self-Injurious Thoughts and Behaviors Interview short form) and corroborated by a clinical risk assessment by a credentialed provider.
- Current manic episode or psychotic symptoms requiring immediate stabilization or hospitalization (as determined by clinical judgment)
- Symptoms of moderate to severe substance use (to include alcohol) warranting immediate intervention based on clinical judgment.
- Other psychiatric disorders severe enough to warrant designation as the primary disorder as determined by clinician judgment
- Pregnancy or breastfeeding
- Current anticoagulant use
- History of bleeding disorder
- Infection or mass at injection site
- Myocardial infarction within 6 months of procedure
- Pathologic bradycardia or irregularities of heart rate or rhythm
- Symptomatic hypotension
- Phrenic or laryngeal nerve palsy
- History of glaucoma
- Uncontrolled seizure disorder
- History of allergy to local anesthetics
- Current use of Class III antiarrhythmics
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Stellate Ganglion Block
One time administration of a stellate ganglion block |
6.5cc of Ropivacaine hydrochloride (HCl) 0.5%, one time into the stellate ganglion
Outros nomes:
|
|
Comparador de Placebo: Sham SGB
One time administration |
6.5cc of Normal Saline one time into the stellate ganglion. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change from baseline in Clinician-Administered PTSD Scale-DSM 5 (CAPS-5)
Prazo: Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
A 30-item structured interview used to assess change symptoms of PTSD. Questions target the onset and duration of symptoms, subjective distress, impact on social and occupational functioning. Total severity scores range from 0 to 80 with higher score indicative of greater PTSD severity. The measure can also be used to confirm the presence of a PTSD diagnosis. |
Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
|
Change from baseline in Posttraumatic Stress Disorder Checklist -DSM 5 (PCL-5)
Prazo: Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
A 20-item self-report measure that assesses the presence and change in severity of PTSD symptoms using the Diagnostic and Statistical Manual of mental disorders (DSM-5). Total severity scores range from 0 to 80 with higher score indictive of greater PTSD severity. |
Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Patient Health Questionnaire-9 items (PHQ-9)
Prazo: Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
A 9-item self-report measure that assesses the presence and change in severity of depressive symptoms. Total scores range from 0 to 27 with higher scores reflective of greater severity. |
Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
|
General Anxiety Disorder Screener - 7 Items (GAD-7)
Prazo: Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
A 9-item self-report measure that assesses the presence and change in severity of general anxiety symptoms. Total scores range from 0 to 21 with higher scores reflective of greater severity. |
Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
|
Posttraumatic Cognitions Inventory (PTCI)
Prazo: Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
A 36-item self-report measure that assesses change in self-blame, negative cognitions about self, and negative cognitions about the world following trauma exposure. Total scores range from 33 to 231 with higher scores reflective of more problematic cognitions. |
Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
|
Psychophysiological arousal - Galvanic Skin Response
Prazo: Two weeks
|
Change in Psychophysiological data collected from a smart watch measuring galvanic skin response |
Two weeks
|
|
Psychophysiological arousal - Skin Temperature
Prazo: Two weeks
|
Change in Psychophysiological data collected from a smart watch measuring skin temperature |
Two weeks
|
|
Psychophysiological arousal - Heart Rate
Prazo: Two weeks
|
Change in Psychophysiological data collected from a smart watch measuring heart rate |
Two weeks
|
|
Psychophysiological arousal - Interbeat Interval
Prazo: Two weeks
|
Change in Psychophysiological data collected from a smart watch measuring interbeat interval |
Two weeks
|
|
Psychophysiological arousal - Three-Dimensional Accelerometer Movement
Prazo: Two weeks
|
Change in Psychophysiological data collected from a smart watch measuring three-dimensional accelerometer movement |
Two weeks
|
|
Psychophysiological arousal - Electrodermal Activity
Prazo: Two weeks
|
Change in Psychophysiological data collected from a smart watch measuring electrodermal activity |
Two weeks
|
|
Psychophysiological arousal - Photoplethysmography
Prazo: Two weeks
|
Change in Psychophysiological data collected from a smart watch measuring photoplethysmography |
Two weeks
|
Colaboradores e Investigadores
Colaboradores
Investigadores
- Investigador principal: Alan Peterson, PhD, The University of Texas Health Science Center at San Antonio
Publicações e links úteis
Publicações Gerais
- Lipov EG, Joshi JR, Lipov S, Sanders SE, Siroko MK. Cervical sympathetic blockade in a patient with post-traumatic stress disorder: a case report. Ann Clin Psychiatry. 2008 Oct-Dec;20(4):227-8. doi: 10.1080/10401230802435518. No abstract available.
- Lynch JH, Mulvaney SW, Kim EH, de Leeuw JB, Schroeder MJ, Kane SF. Effect of Stellate Ganglion Block on Specific Symptom Clusters for Treatment of Post-Traumatic Stress Disorder. Mil Med. 2016 Sep;181(9):1135-41. doi: 10.7205/MILMED-D-15-00518.
- Mulvaney SW, Lynch JH, Hickey MJ, Rahman-Rawlins T, Schroeder M, Kane S, Lipov E. Stellate ganglion block used to treat symptoms associated with combat-related post-traumatic stress disorder: a case series of 166 patients. Mil Med. 2014 Oct;179(10):1133-40. doi: 10.7205/MILMED-D-14-00151.
- Hanling SR, Hickey A, Lesnik I, Hackworth RJ, Stedje-Larsen E, Drastal CA, McLay RN. Stellate Ganglion Block for the Treatment of Posttraumatic Stress Disorder: A Randomized, Double-Blind, Controlled Trial. Reg Anesth Pain Med. 2016 Jul-Aug;41(4):494-500. doi: 10.1097/AAP.0000000000000402.
- Odosso RJ, Petta L. The Efficacy of the Stellate Ganglion Block as a Treatment Modality for Posttraumatic Stress Disorder Among Active Duty Combat Veterans: A Pilot Program Evaluation. Mil Med. 2021 Jul 1;186(7-8):e796-e803. doi: 10.1093/milmed/usaa246.
- Peterson AL, Blount TH, Foa EB, Brown LA, McLean CP, Mintz J, Schobitz RP, DeBeer BR, Mignogna J, Fina BA, Evans WR, Synett S, Hall-Clark BN, Rentz TO, Schrader C, Yarvis JS, Dondanville KA, Hansen H, Jacoby VM, Lara-Ruiz J, Straud CL, Hale WJ, Shah D, Koch LM, Gerwell KM, Young-McCaughan S, Litz BT, Meyer EC, Blankenship AE, Williamson DE, Roache JD, Javors MA, Sharrieff AM, Niles BL, Keane TM; Consortium to Alleviate PTSD. Massed vs Intensive Outpatient Prolonged Exposure for Combat-Related Posttraumatic Stress Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2023 Jan 3;6(1):e2249422. doi: 10.1001/jamanetworkopen.2022.49422.
- Foa EB, McLean CP, Zang Y, Rosenfield D, Yadin E, Yarvis JS, Mintz J, Young-McCaughan S, Borah EV, Dondanville KA, Fina BA, Hall-Clark BN, Lichner T, Litz BT, Roache J, Wright EC, Peterson AL; STRONG STAR Consortium. Effect of Prolonged Exposure Therapy Delivered Over 2 Weeks vs 8 Weeks vs Present-Centered Therapy on PTSD Symptom Severity in Military Personnel: A Randomized Clinical Trial. JAMA. 2018 Jan 23;319(4):354-364. doi: 10.1001/jama.2017.21242.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Transtornos Relacionados a Traumas e Estressores
- Transtornos Mentais, Desordem Mental
- Transtornos de Estresse Traumático
- Transtornos de Estresse Pós-Traumático
- Produtos químicos orgânicos
- Preparações farmacêuticas
- Anilides
- Amidas
- Compostos de anilina
- Aminas
- Soluções cristalóides
- Soluções isotônicas
- Soluções
- Ropivacaína
- Solução salina
Outros números de identificação do estudo
- HSC20230087H
- W81XWH2220055 (Número de outro subsídio/financiamento: Department of Defense)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .